[Adjuvant chemotherapy in breast cancer: present status]

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Pharmacology

Background:

• Axillary lymph node status is a critical prognostic factor in primary breast cancer.
• Adjuvant chemotherapy aims to improve survival outcomes post-surgery.
• Informed consent and controlled study conditions are essential for adjuvant chemotherapy administration.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy in primary breast cancer.
• To identify patient subgroups that benefit most from adjuvant chemotherapy.
• To determine optimal timing and intensity of adjuvant chemotherapy.

Main Methods:

• Analysis of prognostic factors, including lymph node status.
• Assessment of relapse-free survival and overall survival in breast cancer patients.
• Comparison of chemotherapy effects across different menopausal statuses and lymph node involvement levels.

Main Results:

• Adjuvant chemotherapy can prolong relapse-free survival, though not always significantly.
• Efficacy decreases with increased lymph node involvement.
• Pre-menopausal patients with 1-3 affected lymph nodes show the greatest benefit.
• Short-term chemotherapy (up to 6 months) appears sufficient.

Conclusions:

• Adjuvant chemotherapy is most beneficial for pre-menopausal patients with limited lymph node metastasis.
• Early initiation of chemotherapy post-surgery (around the 14th day) is recommended.
• The intensity of chemotherapy is crucial, with intravenous administration preferred.